A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor
What is the purpose of this trial?
To determine the progression-free survival (PFS) of patients with refractory GIST treated with AUY922.
- 18 Years and older
- Sarah Cannon Research Institute Oncology Research Consortium
- Last Updated:
- Study HIC#: